《2020 ESC/HFA Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies》: What is new?
10.3760/cma.j.cn114452-20210105-00006
- VernacularTitle:《2020 ESC/HFA血清生物标志物在癌症治疗中心脏毒性监测中的作用声明》解读
- Author:
Xinxin ZHANG
1
;
Yanli ZHANG
;
Fengqi FANG
;
Jiwei LIU
;
Yunlong XIA
;
Ying LIU
Author Information
1. 大连医科大学附属第一医院心内科，大连 116011
- Keywords:
Oncological cardiology;
Biological markers
- From:
Chinese Journal of Laboratory Medicine
2021;44(7):652-656
- CountryChina
- Language:Chinese
-
Abstract:
Detection of serum biomarkers is an important strategy for the diagnosis of cardiovascular diseases. The roles of serum biomarker detection have become increasingly valuable in the baseline risk stratification among cancer patients in recent years. The Cardio-oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology newly proposed the “role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies”. By evaluating the characteristics of cardiac biomarkers in cancer patients receiving cardiotoxic cancer therapy, this statement discussed the mechanism, clinical application, value on monitoring and prognosis of the two main biomarkers,cardiac troponin and natriuretic peptide on chemotherapy induced cardiac toxic responses. The purpose of this statement is to help establish the multidisciplinary collaborative diagnosis and treatment strategies and provide a clinical framework, and guide clinicians to select appropriate serum biomarker monitoring programs based on risk stratification to prevent cardiovascular disease in cancer patients.
